Britians first medical schoolThe first fixed-combination, cutaneous foam spray for the once-daily topical treatment of all extents of plaque psoriasis for patients who are 18 years or older has been launched in the UK.

Data shows that Enstilar is a more effective topical combination treatment than those currently available, is generally well-tolerated, with more than half of patients in clinical trials experiencing significant visible signs of improvement within four weeks and with some patients seeing improvements at one week.

This treatment can also improve patients’ quality of life (QoL).5 75% of patients feel that their quality of life is significantly impacted by psoriasis, both emotionally and physically.5 81% of psoriasis patients using Enstilar foam spray in trials reported QoL improvements after four weeks, with more than 70% seeing a reduction in itch-related sleep loss. The symptomatic relief experienced by the majority of patients may be attributed to the cooling effect of the new foam spray.

 "Enstilar foam spray represents a welcome new choice of topical therapy for people with plaque psoriasis, particularly those who wish to explore new options with their GP and/or whose next step would be a referral to consider transitioning to systemic therapy", comments Professor Chris Griffiths, Foundation Professor of Dermatology, The University of Manchester,"Clinical data point to the superior efficacy of Enstilar over other topical combination therapies and to a favourable safety profile."

“We are delighted that there is a new, effective treatment choice now available to treat plaque psoriasis, an area of significant unmet need” comments John Warne, Founder, Psoriasis Help Organisation, “Over 1.5 million people across the UK are living each day with the significant challenges of this chronic skin condition so we welcome new options to help them take back control.”